A relaxed discrimination of 2′-O-methyl-GTP relative to GTP between de novo and elongative RNA synthesis by the hepatitis c RNA-dependent RNA polymerase NS5B

被引:34
作者
Dutartre, H
Boretto, J
Guillemot, JC
Canard, B
机构
[1] CNRS, F-13288 Marseille 9, France
[2] Univ Aix Marseille I & II, UMR 6098, Ecole Super Ingn Luminy, F-13288 Marseille 9, France
关键词
D O I
10.1074/jbc.M410191200
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Several nucleotide analogues have been described as inhibitors of NS5B, the essential viral RNA-dependent RNA polymerase of hepatitis C virus. However, their precise mode of action remains poorly defined at the molecular level, much like the different steps of de novo initiation of viral RNA synthesis. Here, we show that before elongation, de novo RNA synthesis is made of at least two distinct kinetic phases, the creation of the first phosphodiester bond being the most efficient nucleotide incorporation event. We have studied 2'-O-methyl-GTP as an inhibitor of NS5B-directed RNA synthesis. As a nucleotide competitor of GTP in RNA synthesis, 2'-O-methyl-GTP is able to act as a chain terminator and inhibit RNA synthesis. Relative to GTP, we find that this analogue is strongly discriminated against at the initiation step (similar to150-fold) compared with similar to2-fold at the elongation step. Interestingly, discrimination of the 2'-O-methyl-GTP at initiation is suppressed in a variant NS5B deleted in a subdomain critical for initiation (the "flap," encompassing amino acids 443-454), but not in P495L NS5B, which shows a selective alteration of transition from initiation to elongation. Our results demonstrate that the conformational change occurring between initiation and elongation is dependent on the allosteric GTP-binding site and relaxes nucleotide selectivity. RNA elongation may represent the most probable target of 2'-modified nucleotide analogues, because it is more permissive to inhibition than initiation.
引用
收藏
页码:6359 / 6368
页数:10
相关论文
共 42 条
[31]   Canonical 3′-deoxyribonucleotides as a chain terminator for HCVNS5B RNA-dependent RNA polymerase [J].
Shim, J ;
Larson, G ;
Lai, V ;
Naim, S ;
Wu, JZ .
ANTIVIRAL RESEARCH, 2003, 58 (03) :243-251
[32]   Selection of 3′-template bases and initiating nucleotides by hepatitis C virus NS5B RNA-dependent RNA polymerase [J].
Shim, JH ;
Larson, G ;
Wu, JZ ;
Hong, Z .
JOURNAL OF VIROLOGY, 2002, 76 (14) :7030-7039
[33]   Spontaneous resolution of chronic hepatitis C virus disease after withdrawal of immunosuppression [J].
Somsouk, MA ;
Lauer, GM ;
Casson, D ;
Terella, A ;
Day, CL ;
Walker, BD ;
Chung, RT .
GASTROENTEROLOGY, 2003, 124 (07) :1946-1949
[34]   MECHANISM OF ACTION OF 1-BETA-D-RIBOFURANOSYL-1,2,4-TRIAZOLE-3-CARBOXAMIDE (VIRAZOLE) - NEW BROAD-SPECTRUM ANTIVIRAL AGENT [J].
STREETER, DG ;
WITKOWSKI, JT ;
KHARE, GP ;
SIDWELL, RW ;
BAUER, RJ ;
ROBINS, RK ;
SIMON, LN .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1973, 70 (04) :1174-1178
[35]   Mechanism of action and antiviral activity of benzimidazole-based allosteric inhibitors of the hepatitis C virus RNA-dependent RNA polymerase [J].
Tomei, L ;
Altamura, S ;
Bartholomew, L ;
Biroccio, A ;
Ceccacci, A ;
Pacini, L ;
Narjes, F ;
Gennari, N ;
Bisbocci, M ;
Incitti, I ;
Orsatti, L ;
Harper, S ;
Stansfield, I ;
Rowley, M ;
De Francesco, R ;
Migliaccio, G .
JOURNAL OF VIROLOGY, 2003, 77 (24) :13225-13231
[36]   Enzymatic characterization of the full-length and C-terminally truncated hepatitis C virus RNA polymerases: Function of the last 21 amino acids of the C terminus in template binding and RNA synthesis [J].
Vo, NV ;
Tuler, JR ;
Lai, MMC .
BIOCHEMISTRY, 2004, 43 (32) :10579-10591
[37]   Mutagenic and inhibitory effects of ribavirin on hepatitis C virus RNA polymerase [J].
Vo, NV ;
Young, KC ;
Lai, MMC .
BIOCHEMISTRY, 2003, 42 (35) :10462-10471
[38]  
Walker Michelle P., 2003, Antiviral Chemistry & Chemotherapy, V14, P1
[39]   Epidemiology of hepatitis C: Geographic differences and temporal trends [J].
Wasley, A ;
Alter, MJ .
SEMINARS IN LIVER DISEASE, 2000, 20 (01) :1-16
[40]  
Wu Jim Zhen, 2003, Current Drug Targets - Infectious Disorders, V3, P207, DOI 10.2174/1568005033481114